AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Clinical trial NCT06265220 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06265220
Sponsor: Artiva Biotherapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Lupus Nephritis - WHO Class III Lupus Nephritis - WHO Class IV Refractory Systemic Lupus Erythematosus SLE

Start date: 2024-04-03
Primary completion: 2027-08-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.